JP2022537349A5 - - Google Patents
Info
- Publication number
- JP2022537349A5 JP2022537349A5 JP2021575326A JP2021575326A JP2022537349A5 JP 2022537349 A5 JP2022537349 A5 JP 2022537349A5 JP 2021575326 A JP2021575326 A JP 2021575326A JP 2021575326 A JP2021575326 A JP 2021575326A JP 2022537349 A5 JP2022537349 A5 JP 2022537349A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- acceptable salt
- compound according
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025061199A JP7844707B2 (ja) | 2019-06-19 | 2025-04-02 | 療法に使用するためのｐａｒｐ１４の標的タンパク質分解 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962863357P | 2019-06-19 | 2019-06-19 | |
| US62/863,357 | 2019-06-19 | ||
| PCT/US2020/038377 WO2020257416A1 (en) | 2019-06-19 | 2020-06-18 | Targeted protein degradation of parp14 for use in therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025061199A Division JP7844707B2 (ja) | 2019-06-19 | 2025-04-02 | 療法に使用するためのｐａｒｐ１４の標的タンパク質分解 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022537349A JP2022537349A (ja) | 2022-08-25 |
| JP2022537349A5 true JP2022537349A5 (enExample) | 2023-06-27 |
Family
ID=71527971
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021575326A Pending JP2022537349A (ja) | 2019-06-19 | 2020-06-18 | 療法に使用するためのｐａｒｐ１４の標的タンパク質分解 |
| JP2025061199A Active JP7844707B2 (ja) | 2019-06-19 | 2025-04-02 | 療法に使用するためのｐａｒｐ１４の標的タンパク質分解 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025061199A Active JP7844707B2 (ja) | 2019-06-19 | 2025-04-02 | 療法に使用するためのｐａｒｐ１４の標的タンパク質分解 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20220388985A1 (enExample) |
| EP (1) | EP3986887A1 (enExample) |
| JP (2) | JP2022537349A (enExample) |
| KR (1) | KR20220024098A (enExample) |
| CN (2) | CN114206853A (enExample) |
| AU (1) | AU2020296063B2 (enExample) |
| BR (1) | BR112021025645A2 (enExample) |
| CA (1) | CA3142002A1 (enExample) |
| MA (1) | MA56513A (enExample) |
| SG (1) | SG11202112980TA (enExample) |
| WO (1) | WO2020257416A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2941818T3 (es) * | 2017-12-21 | 2023-05-25 | Ribon Therapeutics Inc | Quinazolinonas como inhibidores de PARP14 |
| WO2022150667A1 (en) * | 2021-01-08 | 2022-07-14 | The Board Of Regents Of The University Of Texas System | Nimbolide analogs and methods of use thereof |
| TW202241426A (zh) * | 2021-01-29 | 2022-11-01 | 美商律幫治療股份有限公司 | 治療發炎疾病之方法 |
| CN114890989B (zh) * | 2022-05-25 | 2024-03-22 | 广东晨康生物科技有限公司 | 一种含氮衍生物为Linker的HDAC8降解剂其制备方法和应用 |
| CN117229224B (zh) * | 2022-06-07 | 2026-05-08 | 中国药科大学 | 喹唑啉-4(3h)-酮类化合物、制法、组合物和应用 |
| MA71624A (fr) | 2022-07-29 | 2025-05-30 | Abbvie Operations Singapore Pte. Ltd. | Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie |
| KR20250055508A (ko) | 2022-07-29 | 2025-04-24 | 애브비 오퍼레이션즈 싱가포르 피티이. 리미티드 | 치료에 사용하기 위한 parp14의 표적 단백질 분해 |
| CN117658983A (zh) * | 2022-09-01 | 2024-03-08 | 浙江文达医药科技有限公司 | 选择性parp1抑制剂 |
| WO2024251205A1 (zh) * | 2023-06-06 | 2024-12-12 | 西藏海思科制药有限公司 | 一种喹唑啉酮衍生物及其在医药上的应用 |
| CN116813640A (zh) * | 2023-06-29 | 2023-09-29 | 成都金瑞基业生物科技有限公司 | 一类抑制并降解parp的化合物及应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015508414A (ja) * | 2012-01-12 | 2015-03-19 | イエール ユニバーシティ | Ｅ３ユビキチンリガーゼによる標的タンパク質および他のポリペプチドの分解増強のための化合物および方法 |
| EP2890696A1 (en) * | 2012-08-29 | 2015-07-08 | Amgen, Inc. | Quinazolinone compounds and derivatives thereof |
| MY180775A (en) * | 2014-04-23 | 2020-12-09 | Incyte Corp | 1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins |
| WO2017197056A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Bromodomain targeting degronimers for target protein degradation |
| EP3535265A4 (en) * | 2016-11-01 | 2020-07-08 | Arvinas, Inc. | PROTACS TARGETING ON TAU PROTEIN AND RELATED METHODS FOR USE |
| EP3580212A4 (en) * | 2017-02-08 | 2021-03-17 | Dana Farber Cancer Institute, Inc. | REGULATION OF CHEMERIC ANTIGEN RECEPTORS |
| EP4310496A3 (en) * | 2017-07-12 | 2024-12-04 | Dana-Farber Cancer Institute, Inc. | Compounds for tau protein degradation |
| ES2941818T3 (es) * | 2017-12-21 | 2023-05-25 | Ribon Therapeutics Inc | Quinazolinonas como inhibidores de PARP14 |
-
2020
- 2020-06-18 KR KR1020217041538A patent/KR20220024098A/ko active Pending
- 2020-06-18 AU AU2020296063A patent/AU2020296063B2/en active Active
- 2020-06-18 WO PCT/US2020/038377 patent/WO2020257416A1/en not_active Ceased
- 2020-06-18 MA MA056513A patent/MA56513A/fr unknown
- 2020-06-18 CN CN202080044704.2A patent/CN114206853A/zh active Pending
- 2020-06-18 CN CN202510536711.9A patent/CN120398840A/zh active Pending
- 2020-06-18 CA CA3142002A patent/CA3142002A1/en active Pending
- 2020-06-18 JP JP2021575326A patent/JP2022537349A/ja active Pending
- 2020-06-18 EP EP20737701.1A patent/EP3986887A1/en active Pending
- 2020-06-18 SG SG11202112980TA patent/SG11202112980TA/en unknown
- 2020-06-18 US US17/619,459 patent/US20220388985A1/en not_active Abandoned
- 2020-06-18 BR BR112021025645A patent/BR112021025645A2/pt unknown
-
2025
- 2025-04-02 JP JP2025061199A patent/JP7844707B2/ja active Active
- 2025-05-22 US US19/216,120 patent/US20260125362A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007524696A5 (enExample) | ||
| ES2197167T3 (es) | Imidazoles trisustituidos con multiples propiedades terapeuticas. | |
| ES2605230T3 (es) | Derivados de indazol sustituidos activos como inhibidores de cinasas | |
| JP2008510828A5 (enExample) | ||
| JP2009532375A5 (enExample) | ||
| JP2016053042A5 (enExample) | ||
| JP2009533369A5 (enExample) | ||
| JP2008504301A5 (enExample) | ||
| HRP20040073B1 (en) | Viral polymerase inhibitors | |
| JP2007536231A5 (enExample) | ||
| GB0113233D0 (en) | Chemical compounds | |
| JP2008540574A5 (enExample) | ||
| JP2018529690A5 (enExample) | ||
| JP2003508394A5 (enExample) | ||
| JP2014524441A5 (enExample) | ||
| JP2006522037A5 (enExample) | ||
| JP2016500653A5 (enExample) | ||
| JP2015535847A5 (enExample) | ||
| JP2024532768A5 (enExample) | ||
| JP2010520214A5 (enExample) | ||
| EA200971063A1 (ru) | Ариламидпиримидоновые соединения | |
| JP2023532128A5 (enExample) | ||
| JP4268871B2 (ja) | ピリミジノン化合物及びその薬剤として許容される塩の製造方法 | |
| JP2017530193A5 (enExample) | ||
| JP2023504542A5 (enExample) |